-
公开(公告)号：US20250135179A1
公开(公告)日：2025-05-01
申请号：US18877697
申请日：2023-07-18
Applicant: MSD International GmbH
Inventor： Brian MULLARKEY , Noel LAHART , John HAYES
Abstract: A connection tool for use in connecting tubing lines is provided. The connection tool includes a housing having a first and second housing portions. The first housing portion includes a first central recess for receiving a body therein, and a first slide track portion extending from the first central recess. The second housing portion is movable relative to the first housing portion and includes a second central recess for receiving the body therein, and a second slide track portion extending from the second central recess. The first and second slide track portions form a sliding handle track when the first and second housing portions are moved to a closed position.
-
公开(公告)号：US12173026B2
公开(公告)日：2024-12-24
申请号：US17266521
申请日：2019-08-05
Applicant: Merck Sharp & Dohme LLC , MSD International GmbH
Inventor： Michelle Machacek , David Witter , Craig Gibeau , Chunhui Huang , Shuhei Kawamura , David L. Sloman , Phieng Siliphaivanh , Ryan Quiroz , Murray Wan , Sebastian Schneider , Charles S. Yeung , Michael H. Reutershan , Timothy J. Henderson , Jean-Laurent Paparin , Houcine Rahali , Jonathan M. E. Hughes , Sulagna Sanyal , Yingchun Ye , David A. Candito , Patrick S. Fier , Steven M. Silverman
IPC: C07H19/14 , A61P35/00 , C07D487/04
Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
-
公开(公告)号：US20230083431A1
公开(公告)日：2023-03-16
申请号：US17783224
申请日：2020-12-15
Applicant: Nicolas C. BOYER , Michael B. GARRIGOU , Sookhee Nicole HA , Chunhui HUANG , Anthony W. PARTRIDGE , Tomi K. SAWYER , Pietro ARONICA , Charles W. JOHANNES , Srinivasaraghavan KANNAN , Chandra S. VERMA , Tsz Ying YUEN , Merck Sharp & Dohme LLC , MSD International GMBH (Singapore Branch) , Agency for Science, Technology and Research
Inventor： Nicolas C. Boyer , Michael B. Garrigou , Sookhee Nicole Ha , Chunhui Huang , Anthony W. Partridge , Tomi K. Sawyer , Pietro Aronica , Charles W. Johannes , Srinivasaraghavan Kannan , Chandra S. Verma , Tsz Ying Yuen
Abstract: The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
-
公开(公告)号：US20220363707A1
公开(公告)日：2022-11-17
申请号：US17266521
申请日：2019-08-05
Applicant: Merck Sharp & Dohme Corp. , MSD International GmbH
Inventor： Michelle Machacek , David Witter , Craig Gibeau , Chunhui Huang , Shuhei Kawamura , David L. Sloman , Phieng Siliphaivanh , Ryan Quiroz , Murray Wan , Sebastian Schneider , Charles S. Yeung , Michael H. Reutershan , Timothy J. Henderson , Jean-Laurent Paparin , Houcine Rahali , Jonathan M. E. Hughes , Sulagna Sanyal , Yingchun Ye , David A. Candito , Patrick S. Fier , Steven M. Silverman
IPC: C07H19/14 , C07D487/04 , A61P35/00
Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
-
Patent Agency Ranking
公开(公告)号：US20160046646A1
公开(公告)日：2016-02-18
申请号：US14777560
申请日：2014-03-10
Applicant: Steven J. BRENEK , Stephanie CARON , Jade D. NELSON , Mark E. WEBSTER , Rodney Matthew WEEKLY , MSD INTERNATIONAL GMBH
Inventor： Steven J. Brenek , Stephane Caron , Jade D. Nelson , Mark E. Webster , Rodney Matthew Weekly
IPC: C07D493/08 , C07D317/26
CPC classification number: C07D493/08 , C07D317/26 , C07D317/42
Abstract: This invention relates to methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT2 and (S)-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, and intermediates useful in the preparation of the said SGLT2 inhibitor.
Abstract translation: 本发明涉及制备钠葡萄糖转运蛋白2（SGLT2）抑制剂，cocrytalline SGLT2和（S）-5-氧代吡咯烷-2-羧酸（L-PGA）复合物的方法，以及可用于制备所述 SGLT2抑制剂。
-
26.发明公开公开(公告)号：US20230265196A1
公开(公告)日：2023-08-24
申请号：US18043602
申请日：2021-09-02
Applicant: PharmAbcine Inc. , Merck Sharp & Dohme B.V. , MSD International GmbH
Inventor： Seon Young Lee , Weon Sup Lee , Jin-San Yoo , Sang Ryeol Shim
CPC classification number: C07K16/2863 , C07K16/2818 , A61P35/04 , A61P35/00 , C07K2317/24 , C07K2317/21
Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed cell Death 1 receptor (PD-1) and a vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist, and the use of the combination therapies for the treatment of a cancer. In an embodiment, the cancer is a glioblastoma, a breast cancer, a triple negative breast cancer, a metastatic breast cancer, or a metastatic triple negative breast cancer.
-
公开(公告)号：US20230027495A1
公开(公告)日：2023-01-26
申请号：US17775279
申请日：2020-11-06
Applicant: Genmab A/S , MSD International GmbH
Inventor： Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
公开(公告)号：US20220088191A1
公开(公告)日：2022-03-24
申请号：US17053753
申请日：2019-05-07
Applicant: Genmab A/S , MSD International GmbH
Inventor： Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
IPC: A61K39/395 , A61K47/68 , A61P35/00
Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
公开(公告)号：US11030750B2
公开(公告)日：2021-06-08
申请号：US16427171
申请日：2019-05-30
Applicant: Merck Sharp & Dohme Corp. , MSD International GmbH
Inventor： Antong Chen , Dongqing Zhang , Ilknur Icke , Belma Dogdas , Sarayu Parimal
Abstract: Approaches for the automatic segmentation of magnetic resonance (MR) images. Machine learning models segment images to identify image features in consecutive frames at different levels of resolution. A neural network block is applied to groups of MR images to produce primary feature maps at two or more levels of resolution. The images in a given group of MR images may correspond to a cycle and have a temporal order. A second RNN block is applied to the primary feature maps to produce two or more output tensors at corresponding levels of resolution. A segmentation block is applied to the two or more output tensors to produce a probability map for the MR images. The first neural network block may be a convolutional neural network (CNN) block. The second neural network block may be a convolutional long short-term (LSTM) block.
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.016 seconds)
